Filing Details

Accession Number:
0001209191-17-045693
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-19 16:45:54
Reporting Period:
2017-07-17
Filing Date:
2017-07-19
Accepted Time:
2017-07-19 16:45:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610876 Jeffrey Chodakewitz C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp Gmda, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-17 573 $96.87 123,084 No 4 M Direct
Common Stock Disposition 2017-07-17 473 $129.61 122,611 No 4 S Direct
Common Stock Disposition 2017-07-17 100 $130.96 122,511 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-07-17 573 $0.00 573 $96.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,178 2024-07-14 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $129.61 (range $129.28 to $130.14).
  3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. The option vests in 16 quarterly installments from 07/15/2014.